Tag: axial spondyloarthritis axspa

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Axial Spondyloarthritis (axSpA) Market Between 2026 And 2030?

The axial spondyloarthritis (axspa) market size has demonstrated robust growth in recent years. It is anticipated to expand from $6.56 billion in 2025 to $7.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be primarily ascribed to factors like increasing awareness of inflammatory spinal disorders, the broader application of TNF inhibitors, enhanced availability of diagnostic imaging, growth within rheumatology specialty care, and initiatives aimed at improving treatment adherence.

The axial spondyloarthritis (axspa) market is set to experience substantial expansion in the upcoming years, with its value projected to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is fueled by factors such as the increasing acceptance of JAK inhibitors and IL therapies, a rise in investments directed towards personalized medicine, the broadening of early screening initiatives, the expanding application of digital platforms for disease monitoring, and continuous advancements in biologic drug development. Noteworthy trends expected over this period include the increased adoption of biologic therapies, a growing reliance on targeted anti-inflammatory drugs, a heightened focus on early diagnosis and disease monitoring, the proliferation of personalized treatment approaches, and enhanced integration of digital health tools.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

Which Core Factors Are Supporting The Expansion Of The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpa) market is anticipated to expand, driven by the growing aging population. This demographic trend signifies an increasing proportion of older individuals within a population. Effectively managing axSpA in older adults offers several advantages, such as enhanced joint function and mobility, better quality of life, protection against spinal structural damage, lower healthcare expenditures, disability prevention, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported 11 million individuals aged over 65 in England in 2023. This number is projected to rise by 10% in the next five years and by 32% by 2043 (equivalent to 1.1 and 3.5 million people, respectively). Furthermore, the 85+ age group, which typically requires the most health and care services, is expected to experience swift growth, increasing by 8.2% over the next five years and by 62.7% by 2043 (representing 126,000 and 956,000 people, respectively). Consequently, the expanding aging demographic is a significant impetus behind the growth of the axial spondyloarthritis (axSpa) market.

How Is Segment Classification Applied In The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Future Of The Axial Spondyloarthritis (axSpA) Market?

Leading companies within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, particularly next-generation biologic drug therapies, to address the increasing need for effective treatments that target inflammation and improve long-term disease control. These biologic therapies modulate specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily alleviate symptoms without directly influencing underlying immune drivers. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, secured marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is indicated for treating adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who show objective signs of inflammation, as evidenced by elevated C-reactive protein. These European Union (EU) authorizations represent the drug’s first global marketing licenses specifically for axial spondyloarthritis.

Who Are The Companies Shaping The Axial Spondyloarthritis (axSpA) Market Landscape?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Access The Complete Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What Is The Largest Regional Market In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Axial Spondyloarthritis (axSpA) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Osteoarthritis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Cervical Spondylosis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Axial Spondyloarthritis (axSpA) Market Between 2026 And 2030?

The axial spondyloarthritis (axspa) market size has demonstrated robust growth in recent years. It is anticipated to expand from $6.56 billion in 2025 to $7.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be primarily ascribed to factors like increasing awareness of inflammatory spinal disorders, the broader application of TNF inhibitors, enhanced availability of diagnostic imaging, growth within rheumatology specialty care, and initiatives aimed at improving treatment adherence.

The axial spondyloarthritis (axspa) market is set to experience substantial expansion in the upcoming years, with its value projected to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is fueled by factors such as the increasing acceptance of JAK inhibitors and IL therapies, a rise in investments directed towards personalized medicine, the broadening of early screening initiatives, the expanding application of digital platforms for disease monitoring, and continuous advancements in biologic drug development. Noteworthy trends expected over this period include the increased adoption of biologic therapies, a growing reliance on targeted anti-inflammatory drugs, a heightened focus on early diagnosis and disease monitoring, the proliferation of personalized treatment approaches, and enhanced integration of digital health tools.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

Which Core Factors Are Supporting The Expansion Of The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpa) market is anticipated to expand, driven by the growing aging population. This demographic trend signifies an increasing proportion of older individuals within a population. Effectively managing axSpA in older adults offers several advantages, such as enhanced joint function and mobility, better quality of life, protection against spinal structural damage, lower healthcare expenditures, disability prevention, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported 11 million individuals aged over 65 in England in 2023. This number is projected to rise by 10% in the next five years and by 32% by 2043 (equivalent to 1.1 and 3.5 million people, respectively). Furthermore, the 85+ age group, which typically requires the most health and care services, is expected to experience swift growth, increasing by 8.2% over the next five years and by 62.7% by 2043 (representing 126,000 and 956,000 people, respectively). Consequently, the expanding aging demographic is a significant impetus behind the growth of the axial spondyloarthritis (axSpa) market.

How Is Segment Classification Applied In The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Future Of The Axial Spondyloarthritis (axSpA) Market?

Leading companies within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, particularly next-generation biologic drug therapies, to address the increasing need for effective treatments that target inflammation and improve long-term disease control. These biologic therapies modulate specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily alleviate symptoms without directly influencing underlying immune drivers. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, secured marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is indicated for treating adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who show objective signs of inflammation, as evidenced by elevated C-reactive protein. These European Union (EU) authorizations represent the drug’s first global marketing licenses specifically for axial spondyloarthritis.

Who Are The Companies Shaping The Axial Spondyloarthritis (axSpA) Market Landscape?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Access The Complete Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What Is The Largest Regional Market In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Axial Spondyloarthritis (axSpA) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Osteoarthritis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Cervical Spondylosis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Colorectal Surgery Market In 2026 And 2030?

The colorectal surgery market has seen rapid expansion in recent years. It is anticipated to grow from $23.83 billion in 2025 to $26.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. This historical growth can be attributed to an increasing prevalence of colorectal disorders, a rising colorectal cancer incidence, the expansion of surgical specialty centers, the growing adoption of laparoscopic procedures, and advancements in surgical device technology.

The colorectal surgery market size is projected to experience substantial growth in the upcoming years, expanding to $38.98 billion by 2030 with a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period can be attributed to factors such as a heightened demand for robotic colorectal procedures, an increased emphasis on early disease detection and intervention, the expansion of ambulatory surgical centers, growing investments in surgical innovation, and a rising preference for minimally invasive treatment options. Key trends anticipated within the same period encompass the increasing adoption of minimally invasive surgical techniques, a rising utilization of advanced endoscopic systems, the growing integration of robotic-assisted surgery, an expansion of single-use surgical instruments, and an enhanced focus on surgical precision and patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/colorectal-surgery-global-market-report

Which Strong Drivers Are Impacting The Colorectal Surgery Market Growth?

The rising occurrence of colorectal cancer is projected to boost the expansion of the colorectal surgery market. Colorectal cancer refers to a malignant condition that develops in the colon or rectum, often starting as benign polyps that can become cancerous over time. The escalation in colorectal cancer cases is attributed to lifestyle factors such as an unhealthy diet and inactive habits, which heighten the likelihood of developing the illness. Colorectal surgery serves to manage colorectal cancer by excising malignant tissues and the impacted portions of the colon or rectum, consequently enhancing patient prognoses and diminishing the potential for disease advancement. For instance, in July 2025, according to the Australian government, Cancer Australia, an Australia-based government agency, approximately 15,542 new colorectal cancer cases were diagnosed in 2024, with an estimated 5,239 deaths in 2023. Therefore, the increasing incidence of colorectal cancer is driving the growth of the colorectal surgery market.

How Are Different Segments Classified In The Colorectal Surgery Market Segment Analysis?

The colorectal surgery market covered in this report is segmented –

1) By Product: Endoscopes, Electrosurgical Devices, Visual Systems And Handheld Instruments, Sealing And Stapling Devices, Ligation Clips And Dilators, Cutting Instruments, Surgical Accessories

2) By Indication: Colon Polyps, Crohn’s Disease, Colorectal Cancer, Colitis, Irritable Bowel Syndrome (IBS), Other Indications

3) By Surgery Type: Right Hemicolectomy, Left Hemicolectomy, Subtotal Hemicolectomy, Low Anterior Resection, Abdomino-Perineal Resection, Other Surgery Types

4) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Endoscopes: Flexible Endoscopes, Rigid Endoscopes, Capsule Endoscopes, Video Endoscopes, Single-Use Endoscopes

2) By Electrosurgical Devices: Monopolar Electrosurgical Devices, Bipolar Electrosurgical Devices, Radiofrequency Electrosurgical Devices, Ultrasonic Electrosurgical Devices

3) By Visual Systems And Handheld Instruments: Surgical Cameras, Light Sources, Displays And Monitors, Laparoscopic Instruments, Handheld Scopes, Imaging Processors

4) By Sealing And Stapling Devices: Surgical Staplers, Vessel Sealers, Hemostatic Devices, Laparoscopic Staplers

5) By Ligation Clips And Dilators: Titanium Clips, Absorbable Clips, Mechanical Clips, Balloon Dilators, Serial Dilators

6) By Cutting Instruments: Scalpels, Surgical Scissors, Needle Holders, Forceps, Ultrasonic Cutting Devices

7) By Surgical Accessories: Surgical Drapes, Sutures, Surgical Gloves, Trocar Systems, Insufflation Devices

Which Trends Are Contributing To Changes In The Colorectal Surgery Market?

Leading companies in the colorectal surgery market are focusing on developing advanced products, including colorectal surgery with AI-enhanced intraoperative ultrasound, to improve surgical precision, reduce intraoperative complications, enhance tumor detection, optimize resection margins, shorten operation times, and ultimately improve patient outcomes. Colorectal Surgery with AI-Enhanced Intraoperative Ultrasound is a surgical methodology for treating conditions of the colon, rectum, and anus, involving the integration of real-time intraoperative ultrasound imaging with artificial intelligence algorithms. For instance, in June 2025, GE HealthCare, a US-based medical technology, digital solutions, and pharmaceutical firm, launched the bkActiv S series. This next-generation intraoperative ultrasound system is designed to enhance precision and confidence during colorectal and pelvic floor procedures. The bkActiv S series improves imaging accuracy, assisting clinicians in performing minimally invasive interventions. Enhanced visualization during procedures contributes to superior patient outcomes and expands the possibilities of nonsurgical colorectal care. This launch underscores GE HealthCare’s dedication to innovation in medical imaging and procedure guidance.

Who Are The Companies Driving Activity In The Colorectal Surgery Market?

Major companies operating in the colorectal surgery market are Johnson & Johnson, Medtronic plc, Stryker Corporation, Olympus Corporation, Intuitive Surgical Inc., Smith & Nephew plc, Steris plc, Karl Storz SE & Co. KG, Cook Medical LLC, Conmed Corporation, Applied Medical Resources Corporation, Richard Wolf GmbH, Laborie Medical Technologies, CMR Surgical Ltd, B. Braun Melsungen AG, Boston Scientific Corporation, Fujifilm Holdings Corporation, Getinge AB, Medline Industries Inc., Ethicon Inc.

Get The Full Colorectal Surgery Market Report:

https://www.thebusinessresearchcompany.com/report/colorectal-surgery-global-market-report

Which Region Accounts For The Largest Portion Of The Colorectal Surgery Market?

North America was the largest region in the colorectal surgery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal surgery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Colorectal Surgery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/colorectal-surgery-global-market-report

Browse Through More Reports Similar to the Global Colorectal Surgery Market 2026, By The Business Research Company

Cosmetic Surgery Market Report 2026

https://www.thebusinessresearchcompany.com/report/cosmetic-surgery-global-market-report

Non Surgical Cosmetic Procedures Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-surgical-cosmetic-procedures-global-market-report

Colorectal Cancer Molecular Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Axial Spondyloarthritis (axSpA) Market Over The 2026–2030 Period?

The axial spondyloarthritis (axspa) market size has shown substantial growth recently. This market is anticipated to expand from $6.56 billion in 2025 to reach $7.09 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be ascribed to several factors, including increasing awareness of inflammatory spinal disorders, the expanded use of TNF inhibitors, improved diagnostic imaging availability, growth in rheumatology specialty care, and increased treatment adherence initiatives.

The market for axial spondyloarthritis (axspa) is projected to experience robust expansion in the coming years, anticipated to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth over the forecast period include the increasing uptake of JAK inhibitors and IL therapies, greater investments in personalized medicine, the broadening of early screening initiatives, an expanding utilization of digital platforms for disease monitoring, and ongoing advancements in biologic drug development. Key trends expected during this period involve a heightened adoption of biologic therapies, an increased deployment of targeted anti-inflammatory medications, an amplified emphasis on early diagnosis and disease surveillance, the expansion of individualized treatment strategies, and improved incorporation of digital health solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Important Drivers Are Guiding The Axial Spondyloarthritis (axSpA) Market Growth?

The axial spondyloarthritis (axSpa) market is anticipated to expand due to the rising aging population. An aging population signifies a demographic trend where a larger proportion or higher percentage of older individuals exists within a population. Effectively managing axSpA in older individuals offers numerous benefits, including enhanced joint function and mobility, better quality of life, prevention of structural damage to the spine, lower healthcare expenditures, prevention of disability, and refined treatment approaches. For instance, Age UK, a UK-registered charity, reported that in 2023, England had 11 million individuals aged over 65. This demographic is projected to grow by 10% over the next five years and by 32% by 2043, translating to an increase of 1.1 million and 3.5 million people, respectively. Furthermore, the population aged 85+, the age group most prone to requiring health and care services, is also forecast to expand rapidly, seeing an 8.2% rise in the next five years and a 62.7% increase by 2043, corresponding to 126,000 and 956,000 people. Consequently, the expanding aging population is fueling the development of the axial spondyloarthritis (axSpa) market.

How Are Different Segments Classified In The Axial Spondyloarthritis (axSpA) Market Segment Analysis?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Evolution Of The Axial Spondyloarthritis (axSpA) Market?

Major companies operating within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, such as next-generation biologic drug therapies, to address the rising demand for effective treatments that target inflammation and enhance long-term disease control. These biologic therapies function by modulating specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily manage symptoms without directly impacting underlying immune drivers. As an illustration, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is prescribed for adults suffering from active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who exhibit objective signs of inflammation, evidenced by elevated C-reactive protein. These specific European Union (EU) authorizations represent the drug’s initial global marketing licenses for axial spondyloarthritis.

Who Are The Companies Driving Activity In The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Get The Full Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Region Holds The Highest Market Share In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Axial Spondyloarthritis (axSpA) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Axial Spondyloarthritis (axSpA) Market Over The 2026–2030 Period?

The axial spondyloarthritis (axspa) market size has shown substantial growth recently. This market is anticipated to expand from $6.56 billion in 2025 to reach $7.09 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.1%. The historical expansion can be ascribed to several factors, including increasing awareness of inflammatory spinal disorders, the expanded use of TNF inhibitors, improved diagnostic imaging availability, growth in rheumatology specialty care, and increased treatment adherence initiatives.

The market for axial spondyloarthritis (axspa) is projected to experience robust expansion in the coming years, anticipated to reach $9.83 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. Factors contributing to this growth over the forecast period include the increasing uptake of JAK inhibitors and IL therapies, greater investments in personalized medicine, the broadening of early screening initiatives, an expanding utilization of digital platforms for disease monitoring, and ongoing advancements in biologic drug development. Key trends expected during this period involve a heightened adoption of biologic therapies, an increased deployment of targeted anti-inflammatory medications, an amplified emphasis on early diagnosis and disease surveillance, the expansion of individualized treatment strategies, and improved incorporation of digital health solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Important Drivers Are Guiding The Axial Spondyloarthritis (axSpA) Market Growth?

The axial spondyloarthritis (axSpa) market is anticipated to expand due to the rising aging population. An aging population signifies a demographic trend where a larger proportion or higher percentage of older individuals exists within a population. Effectively managing axSpA in older individuals offers numerous benefits, including enhanced joint function and mobility, better quality of life, prevention of structural damage to the spine, lower healthcare expenditures, prevention of disability, and refined treatment approaches. For instance, Age UK, a UK-registered charity, reported that in 2023, England had 11 million individuals aged over 65. This demographic is projected to grow by 10% over the next five years and by 32% by 2043, translating to an increase of 1.1 million and 3.5 million people, respectively. Furthermore, the population aged 85+, the age group most prone to requiring health and care services, is also forecast to expand rapidly, seeing an 8.2% rise in the next five years and a 62.7% increase by 2043, corresponding to 126,000 and 956,000 people. Consequently, the expanding aging population is fueling the development of the axial spondyloarthritis (axSpa) market.

How Are Different Segments Classified In The Axial Spondyloarthritis (axSpA) Market Segment Analysis?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

What Trends Are Influencing The Evolution Of The Axial Spondyloarthritis (axSpA) Market?

Major companies operating within the axial spondyloarthritis (axSpA) market are concentrating on developing innovative solutions, such as next-generation biologic drug therapies, to address the rising demand for effective treatments that target inflammation and enhance long-term disease control. These biologic therapies function by modulating specific immune pathways, offering a more precise approach compared to traditional anti-inflammatory drugs, which primarily manage symptoms without directly impacting underlying immune drivers. As an illustration, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is prescribed for adults suffering from active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who exhibit objective signs of inflammation, evidenced by elevated C-reactive protein. These specific European Union (EU) authorizations represent the drug’s initial global marketing licenses for axial spondyloarthritis.

Who Are The Companies Driving Activity In The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Get The Full Axial Spondyloarthritis (axSpA) Market Report:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Region Holds The Highest Market Share In The Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Axial Spondyloarthritis (axSpA) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Axial Spondyloarthritis (axSpA) Market Across 2026–2030?

The market size for axial spondyloarthritis (axspa) has experienced robust growth over recent years. It is anticipated to increase from $6.56 billion in 2025 to $7.09 billion in 2026, expanding at a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the past can be attributed to a heightened awareness of inflammatory spinal disorders, the broadened application of TNF inhibitors, enhanced availability of diagnostic imaging, an increase in specialized rheumatology care, and strengthened efforts toward treatment adherence.

The market for axial spondyloarthritis (axspa) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $9.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth is driven by several factors, including the increasing uptake of JAK inhibitors and IL therapies, growing investments in personalized medicine, the broadening scope of early screening initiatives, wider implementation of digital platforms for disease monitoring, and ongoing advancements in biologic drug development. Key trends anticipated during this forecast period involve the rising embrace of biologic treatments, the increased application of targeted anti-inflammatory medications, an intensified emphasis on early diagnosis and continuous disease monitoring, the development of more personalized treatment strategies, and improved incorporation of digital health technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpa) market is anticipated to expand due to the growing aging population. An aging population signifies a demographic pattern marked by a greater or increasing percentage of older people in a given population. Managing and treating axSpA among the elderly offers advantages such as enhanced joint function and mobility, better quality of life, prevention of spinal structural damage, lower healthcare expenditures, disability prevention, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported that in 2023, England had 11 million individuals over 65 years old. This figure is forecasted to grow by 10% in the upcoming five years and by 32% by 2043 (equivalent to 1.1 and 3.5 million people, respectively). Furthermore, the 85+ age group, which typically requires the most health and care services, is also expected to experience a rapid increase, rising by 8.2% in the next five years and by 62.7% by 2043 (representing 126,000 and 956,000 people, respectively). Consequently, the expanding aging demographic is fueling the expansion of the axial spondyloarthritis (axSpa) market.

What Segmentation Levels Are Considered In The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

Which Trends Are Impacting The Growth Of The Axial Spondyloarthritis (axSpA) Market?

Companies operating within the axial spondyloarthritis (axSpA) market are dedicated to developing advanced solutions, such as next-generation biologic drug therapies, to satisfy the growing need for effective treatments that tackle inflammation and improve long-term disease management. These biologic therapies work by modulating specific immune pathways, offering a more precise strategy compared to traditional anti-inflammatory drugs, which primarily alleviate symptoms without directly influencing the underlying immune factors. For example, in June 2023, UCB SA, a pharmaceutical company based in Belgium, secured approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This drug is intended for treating adults diagnosed with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who exhibit objective signs of inflammation, indicated by elevated C-reactive protein. These European Union (EU) authorizations signify the drug’s inaugural global marketing licenses for axial spondyloarthritis.

Which Leading Firms Are Contributing To The Growth Of The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Read the full axial spondyloarthritis (axspa) market report here:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Regions Are Projected To Dominate The Axial Spondyloarthritis (axSpA) Market In The Coming Years?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Axial Spondyloarthritis (axSpA) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Osteoarthritis Global Market Report

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Global Market Report

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Cervical Spondylosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model